176 related articles for article (PubMed ID: 29308723)
1. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
Janiga J; Kentley J; Nabhan C; Abdulla F
Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
[TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab in Relapsed and Refractory Mycosis Fungoides and Sézary Syndrome: A Multicenter Phase II Study.
Khodadoust MS; Rook AH; Porcu P; Foss F; Moskowitz AJ; Shustov A; Shanbhag S; Sokol L; Fling SP; Ramchurren N; Pierce R; Davis A; Shine R; Li S; Fong S; Kim J; Yang Y; Blumenschein WM; Yearley JH; Das B; Patidar R; Datta V; Cantu E; McCutcheon JN; Karlovich C; Williams PM; Subrahmanyam PB; Maecker HT; Horwitz SM; Sharon E; Kohrt HE; Cheever MA; Kim YH
J Clin Oncol; 2020 Jan; 38(1):20-28. PubMed ID: 31532724
[TBL] [Abstract][Full Text] [Related]
3. Final results of a multicenter phase II study of the purine nucleoside phosphorylase (PNP) inhibitor forodesine in patients with advanced cutaneous T-cell lymphomas (CTCL) (Mycosis fungoides and Sézary syndrome).
Dummer R; Duvic M; Scarisbrick J; Olsen EA; Rozati S; Eggmann N; Goldinger SM; Hutchinson K; Geskin L; Illidge TM; Giuliano E; Elder J; Kim YH
Ann Oncol; 2014 Sep; 25(9):1807-1812. PubMed ID: 24948692
[TBL] [Abstract][Full Text] [Related]
4. Therapeutic reduction of cell-mediated immunosuppression in mycosis fungoides and Sézary syndrome.
Geskin LJ; Akilov OE; Kwon S; Schowalter M; Watkins S; Whiteside TL; Butterfield LH; Falo LD
Cancer Immunol Immunother; 2018 Mar; 67(3):423-434. PubMed ID: 29204699
[TBL] [Abstract][Full Text] [Related]
5. Advances in the treatment of mycoses fungoides and Sézary syndrome: a narrative update in skin-directed therapies and immune-based treatments.
Stuver R; Geller S
Front Immunol; 2023; 14():1284045. PubMed ID: 37868986
[TBL] [Abstract][Full Text] [Related]
6. Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors.
Quadri I; Reneau JC; Hanel W; Chung CG
Front Immunol; 2023; 14():1291259. PubMed ID: 38022633
[TBL] [Abstract][Full Text] [Related]
7. Cutaneous Lymphoma International Consortium Study of Outcome in Advanced Stages of Mycosis Fungoides and Sézary Syndrome: Effect of Specific Prognostic Markers on Survival and Development of a Prognostic Model.
Scarisbrick JJ; Prince HM; Vermeer MH; Quaglino P; Horwitz S; Porcu P; Stadler R; Wood GS; Beylot-Barry M; Pham-Ledard A; Foss F; Girardi M; Bagot M; Michel L; Battistella M; Guitart J; Kuzel TM; Martinez-Escala ME; Estrach T; Papadavid E; Antoniou C; Rigopoulos D; Nikolaou V; Sugaya M; Miyagaki T; Gniadecki R; Sanches JA; Cury-Martins J; Miyashiro D; Servitje O; Muniesa C; Berti E; Onida F; Corti L; Hodak E; Amitay-Laish I; Ortiz-Romero PL; Rodríguez-Peralto JL; Knobler R; Porkert S; Bauer W; Pimpinelli N; Grandi V; Cowan R; Rook A; Kim E; Pileri A; Patrizi A; Pujol RM; Wong H; Tyler K; Stranzenbach R; Querfeld C; Fava P; Maule M; Willemze R; Evison F; Morris S; Twigger R; Talpur R; Kim J; Ognibene G; Li S; Tavallaee M; Hoppe RT; Duvic M; Whittaker SJ; Kim YH
J Clin Oncol; 2015 Nov; 33(32):3766-73. PubMed ID: 26438120
[TBL] [Abstract][Full Text] [Related]
8. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2023.
Latzka J; Assaf C; Bagot M; Cozzio A; Dummer R; Guenova E; Gniadecki R; Hodak E; Jonak C; Klemke CD; Knobler R; Morrris S; Nicolay JP; Ortiz-Romero PL; Papadavid E; Pimpinelli N; Quaglino P; Ranki A; Scarisbrick J; Stadler R; Väkevä L; Vermeer MH; Wehkamp U; Whittaker S; Willemze R; Trautinger F
Eur J Cancer; 2023 Dec; 195():113343. PubMed ID: 37890355
[TBL] [Abstract][Full Text] [Related]
9. Cost-utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma.
Muszbek N; Remak E; Xin Q; McNamara L; Jones T
J Comp Eff Res; 2023 Jul; 12(7):CER. PubMed ID: 37338181
[No Abstract] [Full Text] [Related]
10. Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.
Quaglino P; Maule M; Prince HM; Porcu P; Horwitz S; Duvic M; Talpur R; Vermeer M; Bagot M; Guitart J; Papadavid E; Sanches JA; Hodak E; Sugaya M; Berti E; Ortiz-Romero P; Pimpinelli N; Servitje O; Pileri A; Zinzani PL; Estrach T; Knobler R; Stadler R; Fierro MT; Alberti Violetti S; Amitay-Laish I; Antoniou C; Astrua C; Chaganti S; Child F; Combalia A; Fabbro S; Fava P; Grandi V; Jonak C; Martinez-Escala E; Kheterpal M; Kim EJ; McCormack C; Miyagaki T; Miyashiro D; Morris S; Muniesa C; Nikolaou V; Ognibene G; Onida F; Osella-Abate S; Porkert S; Postigo-Llorente C; Ram-Wolff C; Ribero S; Rogers K; Sanlorenzo M; Stranzenbach R; Spaccarelli N; Stevens A; Zugna D; Rook AH; Geskin LJ; Willemze R; Whittaker S; Hoppe R; Scarisbrick J; Kim Y
Ann Oncol; 2017 Oct; 28(10):2517-2525. PubMed ID: 28961843
[TBL] [Abstract][Full Text] [Related]
11. Overall survival in the UK in mycosis fungoides or Sézary syndrome cutaneous T-cell lymphoma: comparative effectiveness of mogamulizumab versus current standard of care.
Hawkins N; Muszbek N; Evans R; McNamara L; Jones T
J Comp Eff Res; 2023 Oct; 12(10):e230017. PubMed ID: 37642410
[No Abstract] [Full Text] [Related]
12. Cutaneous T-cell Lymphomas: A Single-center Retrospective Analysis.
Kaemmerer T; Guertler A; Clanner-Engelshofen BM; Fuchs C; French LE; Reinholz M
Acta Dermatovenerol Croat; 2023 Dec; 31(4):184-190. PubMed ID: 38651844
[TBL] [Abstract][Full Text] [Related]
13. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas.
Izu-Belloso R; Gainza-Apraiz I; Ortiz-Romero P; Servitje-Bedate O; Fernández de Misa-Cabrera R; Peñate Y; Hernandez-Machin B; Estrach-Panella T; Llamas-Velasco M; Yanguas-Bayona JI; Morillo-Andujar M; Acebo-Mariñas E; Perez-Gala S; Armario-Hita JC; Sanchez-Sambucety P; Ortiz-Brugues A; Eguren-Michelena C; Bielsa-Marsol I; Lopez-Pestaña A; Blanes-Martinez M; Fernandez-Guarino M; Lopez-Lerma I
Actas Dermosifiliogr; 2024 Jun; 115(6):T547-T554. PubMed ID: 38653368
[TBL] [Abstract][Full Text] [Related]
14. Experience With Bexarotene to Treat Cutaneous T-Cell Lymphomas: A Study of the Spanish Working Group of Cutaneous Lymphomas.
Izu-Belloso R; Gainza-Apraiz I; Ortiz-Romero P; Servitje-Bedate O; Fernández de Misa-Cabrera R; Peñate Y; Hernandez-Machin B; Estrach-Panella T; Llamas-Velasco M; Yanguas-Bayona JI; Morillo-Andujar M; Acebo-Mariñas E; Perez-Gala S; Armario-Hita JC; Sanchez-Sambucety P; Ortiz-Brugues A; Eguren-Michelena C; Bielsa-Marsol I; Lopez-Pestaña A; Blanes-Martinez M; Fernandez-Guarino M; Lopez-Lerma I
Actas Dermosifiliogr; 2024 Jun; 115(6):547-554. PubMed ID: 38395224
[TBL] [Abstract][Full Text] [Related]
15. Changes to Registered and Pivotal Clinical Trials after the 2011 Tri-Societies Guidelines for Clinical Endpoints and Response Criteria in Mycosis Fungoides and Sézary Syndrome.
Gunter SJ; Kim EJ
J Invest Dermatol; 2024 Apr; 144(4):855-861.e1. PubMed ID: 37925066
[TBL] [Abstract][Full Text] [Related]
16. An update on mechanisms of pruritus and their potential treatment in primary cutaneous T-cell lymphoma.
Hu M; Scheffel J; Elieh-Ali-Komi D; Maurer M; Hawro T; Metz M
Clin Exp Med; 2023 Dec; 23(8):4177-4197. PubMed ID: 37555911
[TBL] [Abstract][Full Text] [Related]
17. Mogamulizumab combined with extracorporeal photopheresis for the treatment of refractory mycosis fungoides and Sézary syndrome. Report of seven cases.
Rubio-Muniz CA; Sánchez-Velázquez A; Arroyo-Andrés J; Agud-de Dios M; Tarín-Vicente EJ; Falkenhain-López D; Ortiz-Romero PL
J Eur Acad Dermatol Venereol; 2024 Jan; 38(1):e102-e105. PubMed ID: 37611255
[No Abstract] [Full Text] [Related]
18. Mycosis fungoides and Sézary syndrome following dupilumab treatment: experience of two Italian tertiary care centres.
Buffon S; Alberti Violetti S; Avallone G; Venegoni L; Marzano AV; Mastorino L; Fava P; Ribero S; Quaglino P; Ortoncelli M; Ferrucci SM
Clin Exp Dermatol; 2023 Nov; 48(12):1376-1378. PubMed ID: 37596961
[No Abstract] [Full Text] [Related]
19. Predictive and Prognostic Biomarkers in Patients With Mycosis Fungoides and Sézary Syndrome (BIO-MUSE): Protocol for a Translational Study.
Belfrage E; Ek S; Johansson Å; Brauner H; Sonesson A; Drott K
JMIR Res Protoc; 2024 Apr; 13():e55723. PubMed ID: 38436589
[TBL] [Abstract][Full Text] [Related]
20. Histopathological Markers for Target Therapies in Primary Cutaneous Lymphomas.
Sonego B; Ibatici A; Rivoli G; Angelucci E; Sola S; Massone C
Cells; 2023 Nov; 12(22):. PubMed ID: 37998391
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
